BioCentury | Jul 15, 2020
Product Development

University of Queensland COVID-19 vaccine becomes seventh with CEPI funding to enter the clinic

As Moderna readies for Phase III testing of its COVID-19 vaccine after reporting more positive data, multiple other vaccines continue to show progress as countermeasures against the virus. A CEPI-funded candidate from the University of...
BioCentury | Jul 9, 2020
Product Development

CSL testing coagulation factor blocker in COVID-19 patients; plus vaccine deals and plasma trials

As partnerships aimed at preventing COVID-19 or treating early disease continue to form and expand, CSL has begun testing a blood coagulation factor inhibitor for severe COVID-19. The CSL Behring unit of CSL Ltd. (ASX:CSL)...
BioCentury | Jul 1, 2020
Product Development

Accelerating the fight against COVID-19 with real-world data on tests

Almost every aspect of the fight against COVID-19 depends on the ability to determine whether an individual is or has been infected with SARS-CoV-2, but more than six months into the pandemic there is still...
BioCentury | Jun 27, 2020
Deals

Who’ll buy uniQure now?

UniQure’s out-licensing deal for its lead gene therapy program in hemophilia B may have disappointed investors, but that does not preclude the Dutch company from remaining an attractive takeout target. Investors immediately soured on Wednesday’s...
BioCentury | Jun 25, 2020
Deals

June 24 Quick Takes: CSL pays $450M for uniQure’s hemophilia gene therapy; plus Merck-Yumanity, Editas, Compass-Olivia, Century-Empirica, Tetraphase-La Jolla

CSL gets global rights to uniQure gene therapy  CSL Ltd. (ASX:CSL) is paying $450 million up front for an exclusive, worldwide license to commercialize etranacogene dezaparvovec (AMT-061) from uniQure N.V. (NASDAQ:QURE), which is also eligible...
BioCentury | Jun 20, 2020
Deals

Clinical scorecard for COVID-19: lessons from the first wave of controlled trials

Breaking through the noise of poor-quality clinical studies are the first clear signals of a treatment paradigm for COVID-19, indicating how and when to use the two major therapeutic approaches -- attacking the virus and...
BioCentury | Jun 18, 2020
Emerging Company Profile

Lassen emerges from Frazier with over $31M and a mAb for fibrosis and cancer

After incubating in Frazier for a year and half, Lassen emerged from stealth Wednesday with a preclinical program targeting the IL-11 receptor that could be applied to both fibrosis and cancer and enough funds to...
BioCentury | Jun 17, 2020
Politics, Policy & Law

COVAX created to try to avoid global bidding frenzy for COVID-19 vaccines

Panic buying of vaccines by high income countries, mopping up supply and squeezing out lower income countries, is the nightmare postscript to COVID-19 that international health agencies envisage could play out if steps aren’t taken...
BioCentury | Jun 12, 2020
Product Development

June 11 Quick Takes: Sobi licenses Selecta gout therapy; plus Viela’s first approval, CSL, BMS, Sirnaomics’ spinout, Denali-Sanofi

Sobi pays $100M up front for Selecta therapy  Swedish Orphan Biovitrum AB (SSE:SOBI) licensed ex-China rights to SEL-212, a gout therapy from Selecta Biosciences Inc. (NASDAQ:SELB). Selecta will receive $75 million up front and $25...
BioCentury | Jun 11, 2020
Deals

June 10 Quick Takes: Lilly enters deal with Evox on exosome therapies; plus Sanofi-Alphamab, CSL-Vitaeris, Canbridge-UMass and Find’s debut

Lilly partners with Evox on exosome therapies  Eli Lilly and Co. (NYSE:LLY) entered a collaboration and five-target licensing deal with Oxford-based Evox Therapeutics Ltd. to develop and deliver RNAi and antisense oligonucleotides for neurological disorders...
Items per page:
1 - 10 of 490
BioCentury | Jul 15, 2020
Product Development

University of Queensland COVID-19 vaccine becomes seventh with CEPI funding to enter the clinic

As Moderna readies for Phase III testing of its COVID-19 vaccine after reporting more positive data, multiple other vaccines continue to show progress as countermeasures against the virus. A CEPI-funded candidate from the University of...
BioCentury | Jul 9, 2020
Product Development

CSL testing coagulation factor blocker in COVID-19 patients; plus vaccine deals and plasma trials

As partnerships aimed at preventing COVID-19 or treating early disease continue to form and expand, CSL has begun testing a blood coagulation factor inhibitor for severe COVID-19. The CSL Behring unit of CSL Ltd. (ASX:CSL)...
BioCentury | Jul 1, 2020
Product Development

Accelerating the fight against COVID-19 with real-world data on tests

Almost every aspect of the fight against COVID-19 depends on the ability to determine whether an individual is or has been infected with SARS-CoV-2, but more than six months into the pandemic there is still...
BioCentury | Jun 27, 2020
Deals

Who’ll buy uniQure now?

UniQure’s out-licensing deal for its lead gene therapy program in hemophilia B may have disappointed investors, but that does not preclude the Dutch company from remaining an attractive takeout target. Investors immediately soured on Wednesday’s...
BioCentury | Jun 25, 2020
Deals

June 24 Quick Takes: CSL pays $450M for uniQure’s hemophilia gene therapy; plus Merck-Yumanity, Editas, Compass-Olivia, Century-Empirica, Tetraphase-La Jolla

CSL gets global rights to uniQure gene therapy  CSL Ltd. (ASX:CSL) is paying $450 million up front for an exclusive, worldwide license to commercialize etranacogene dezaparvovec (AMT-061) from uniQure N.V. (NASDAQ:QURE), which is also eligible...
BioCentury | Jun 20, 2020
Deals

Clinical scorecard for COVID-19: lessons from the first wave of controlled trials

Breaking through the noise of poor-quality clinical studies are the first clear signals of a treatment paradigm for COVID-19, indicating how and when to use the two major therapeutic approaches -- attacking the virus and...
BioCentury | Jun 18, 2020
Emerging Company Profile

Lassen emerges from Frazier with over $31M and a mAb for fibrosis and cancer

After incubating in Frazier for a year and half, Lassen emerged from stealth Wednesday with a preclinical program targeting the IL-11 receptor that could be applied to both fibrosis and cancer and enough funds to...
BioCentury | Jun 17, 2020
Politics, Policy & Law

COVAX created to try to avoid global bidding frenzy for COVID-19 vaccines

Panic buying of vaccines by high income countries, mopping up supply and squeezing out lower income countries, is the nightmare postscript to COVID-19 that international health agencies envisage could play out if steps aren’t taken...
BioCentury | Jun 12, 2020
Product Development

June 11 Quick Takes: Sobi licenses Selecta gout therapy; plus Viela’s first approval, CSL, BMS, Sirnaomics’ spinout, Denali-Sanofi

Sobi pays $100M up front for Selecta therapy  Swedish Orphan Biovitrum AB (SSE:SOBI) licensed ex-China rights to SEL-212, a gout therapy from Selecta Biosciences Inc. (NASDAQ:SELB). Selecta will receive $75 million up front and $25...
BioCentury | Jun 11, 2020
Deals

June 10 Quick Takes: Lilly enters deal with Evox on exosome therapies; plus Sanofi-Alphamab, CSL-Vitaeris, Canbridge-UMass and Find’s debut

Lilly partners with Evox on exosome therapies  Eli Lilly and Co. (NYSE:LLY) entered a collaboration and five-target licensing deal with Oxford-based Evox Therapeutics Ltd. to develop and deliver RNAi and antisense oligonucleotides for neurological disorders...
Items per page:
1 - 10 of 490